Category Ranking
98%
Total Visits
921
Avg Visit Duration
2 minutes
Citations
20
Article Abstract
This study aims to investigate the effect of reflection at the soft tissue-bone interface on shock wave propagation within soft tissue using finite element methods. Results showed that reflection caused obvious differences in the propagation process and attenuation characteristics of shock waves. The energy flux density (EFD) at the same target was proportional to the impact pressure. Changes in EFD at the target could be estimated using the impact pressure and the distance between the soft tissue-bone interface and the target (RMSE < 0.01). These results provide a reference for evaluating rESWT equipment and optimizing clinical treatment protocols.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1080/10255842.2025.2554255 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Effect of the reflection at the soft tissue-bone interface on propagating characteristics of radial extracorporeal shock wave in soft tissue.
Comput Methods Biomech Biomed Engin
September 2025
School of Biological Science and Medical Engineering, Beihang University, Beijing, China.
This study aims to investigate the effect of reflection at the soft tissue-bone interface on shock wave propagation within soft tissue using finite element methods. Results showed that reflection caused obvious differences in the propagation process and attenuation characteristics of shock waves. The energy flux density (EFD) at the same target was proportional to the impact pressure.
View Article and Find Full Text PDFCoronary Artery Calcium Score as a Predictor of Anthracycline-Induced Cardiotoxicity: The ANTEC Study.
Pharmaceuticals (Basel)
July 2025
Department of Lymphoid Malignancies, Maria Sklodowska-Curie National Research Institute of Oncology, 02-781 Warsaw, Poland.
Many risk factors for cancer therapy-related cardiovascular toxicity overlap with risk factors for atherosclerosis. According to the ESC 2022 Cardio-Oncology Guidelines, coronary computed tomography angiography and coronary artery calcium score are not recommended as part of routine risk assessment prior to oncological treatment. The aim of this study was to prospectively assess the influence of coronary artery calcium score (CAC score) on cancer therapy-related cardiac dysfunction in patients with moderate and high risk of cardiovascular toxicity, qualified for anthracycline treatment.
View Article and Find Full Text PDFEfficacy of radiotherapy and radiotherapy with hyperthermia to delay change of systemic therapy in patients with metastatic melanoma.
Clin Transl Radiat Oncol
November 2025
Department of Soft Tissue/Bone Sarcoma and Melanoma, Maria Sklodowska-Curie National Research Institute of Oncology, Warsaw, Poland.
Background: The use of radiotherapy (RT) and RT with hyperthermia (HT) as a local treatment for oligoprogression in many tumors is becoming increasingly prevalent. However, there is currently limited data regarding RT efficacy in prolonging systemic therapy in melanoma. To address this lack of evidence, we conducted a single-institution study to establish the role of RT and RT + HT in delaying the time to systemic treatment switch in metastatic melanoma (MM).
View Article and Find Full Text PDFPhase II study of retifanlimab in patients with recurrent locally advanced or metastatic Merkel cell carcinoma (POD1UM-201).
J Immunother Cancer
August 2025
Division of Medical Oncology, Department of Medicine, University of Washington and Fred Hutchinson Cancer Center, Seattle, Washington, USA.
Background: POD1UM-201, an open-label, single-arm, phase II multiregional study, evaluated efficacy and tolerability of retifanlimab, a humanized monoclonal antibody targeting programmed cell death protein-1 (PD-1) in chemotherapy-naive patients with recurrent locally advanced or metastatic Merkel cell carcinoma (MCC).
Methods: Patients were enrolled across 34 sites in the USA, Canada, and Europe. Eligible patients were ≥18 years with confirmed recurrent advanced locoregional or metastatic MCC not amenable to surgery or radiation therapy, had not received previous systemic treatment, had measurable disease, and Eastern Cooperative Oncology Group performance status 0-1.
How to foster new treatment development in ultra-rare tumours? Joint EMA-EORTC multi-stakeholder workshops on ultra-rare sarcomas as a model for rare cancers.
Cancer Treat Rev
August 2025
Icelandic Medicines Agency, Iceland.
Ultra-rare sarcomas (URS) and ultra-rare cancers (URC) represent a unique challenge in oncology due to their rarity, heterogeneity, and the severe unmet clinical needs of affected patients. In 2024, the European Medicines Agency (EMA) and the European Organisation for Research and Treatment of Cancer (EORTC) convened two multi-stakeholder workshops, bringing together regulators, clinicians, researchers, and patient advocates. These workshops aimed to explore innovative strategies for treatment development and establish a framework for future collaboration.
View Article and Find Full Text PDF